| 07/31/2026 6:10 AM | Werewolf Therapeutics (1785530) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/31/2026 6:06 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/08/2026 4:34 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/06/2026 4:18 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:18 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:18 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:19 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:19 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:19 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/02/2026 7:26 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/29/2026 6:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for HOWL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/29/2026 4:29 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:39 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/22/2026 5:59 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 6:02 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/16/2026 5:01 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 7:16 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/11/2026 7:13 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/10/2026 4:20 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 5:13 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 5:42 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 5:51 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/28/2026 4:02 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:04 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/26/2026 5:18 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/20/2026 5:08 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:03 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Ray Dalio: Buy Gold. Get Paid. (Ad) Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and crypto as U.S. debt continues to climb and fiat currencies lose purchasing power.
A little-known $15 fund is already converting gold's momentum into monthly income - as much as $1,152 per month. No gold bars, no mining stocks, just consistent payouts. See how to follow Dalio's gold strategy and collect monthly income |
| 05/14/2026 4:23 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/13/2026 3:06 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 6:56 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/12/2026 6:47 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 5:26 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 3:31 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:33 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:33 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/07/2026 5:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/05/2026 6:04 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/04/2026 5:00 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:52 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 6:16 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:59 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 6:07 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/27/2026 6:12 AM | Werewolf Therapeutics (1785530) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/24/2026 4:26 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/11/2026 2:46 PM | Longwood Fund III, L.P. (1640546) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13G/A | |
| 02/06/2026 3:41 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/20/2026 3:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/16/2026 4:36 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 01/15/2026 4:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 4:09 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 4:12 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:58 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:59 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:57 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/02/2026 4:32 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad) In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night.
Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. See Jim Rickards' full market warning and what it means for your portfolio |
| 12/29/2025 5:59 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 12/29/2025 4:27 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 3:45 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:45 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:46 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:47 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 3:55 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |